Aurobindo Pharma is reportedly aiming to achieve $3 billion in revenues in next two years. In this regard, the company will increase number of launches in the US market. Even though Aurobindo had launched as many as 28 products in the US market in the previous year, it has carried forward 7 ANDA final approvals received during the year for the launch in the current year.
The company as on March, 2016 has filed 398 ANDAs on a cumulative basis, out of which 251 ANDAs were approved including 36 tentative approvals and balance 147 ANDAs are under review by the USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: